
research
Singing Meets Science: Texas A&M Researchers ‘See Sound’ To Quiet Future Flights
Jun 17, 2025 • 4 min. readBy blending choral performance with aerospace engineering, a student-built acoustic imaging instrument helps researchers track sound with precision — a key step toward designing quieter airplanes.
Texas A&M Launches Statewide Dementia Research Initiative To Tackle Alzheimer’s Crisis
Jun 16, 2025 • 4 min. readWith over $1.2 million in seed funding, the Dementia & Alzheimer’s Research Initiative (DARI) unites researchers across disciplines to drive breakthroughs in prevention, diagnosis and care.
How Youth Sports Creates Future Leaders Or Future Cheaters
Jun 13, 2025 • 4 min. readYouth sports teaches children vital life skills through competition, but according to a Texas A&M professor, this could be detrimental if it causes kids to rationalize bad behavior.
A sweetener commonly found in chewing gum can replace toxic additives in hydrogels used to diagnose and treat a variety of medical conditions.
How U.S. Companies Can Fight Back Against Import Competition
Jun 9, 2025 • 3 min. readTexas A&M research reveals the power of marketing in the battle against Chinese imports.
Creatine Is Safe, Effective And Important For Everyone, Longtime Researcher Says
Jun 9, 2025 • 3 min. readA Texas A&M University expert explains the health benefits of the supplement.
Study Reveals How Fatal School Shootings Disrupt Local Economies
Jun 6, 2025 • 3 min. readNew research co-authored by a Texas A&M expert reveals that anxiety following school shootings reduces spending in public spaces for months, and the impact is felt more in liberal-leaning counties.
Research led by Texas A&M’s Department of Kinesiology and Sport Management explores benefits of riding as therapy.
A new model uses site characterization data and Bayesian statistics to protect offshore energy infrastructure from submarine landslides.
Human Clinical Trial Begins For Texas A&M-Discovered Drug To Treat Angelman Syndrome
Jun 2, 2025 • 6 min. readDeveloped by biopharmaceutical company Ultragenyx, GTX-102 is the first clinically developed drug targeting the genetic causes of Angelman syndrome rather than symptoms.